Signal · Supply Chain & Logistics
Trump has another tariff plan to reshore generic drug production. Will it work?
What the source reported
Source-reported<figure><div><img src="https://imgproxy.divecdn.com/XGJMFyYYqzzDx3Puoe76Ns3YNaOpgS9dioqbTYWkSEI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjA4MTg1MTYzX2puUGZkYlUuanBn.webp"/></div></figure><p>The president’s most recent tariff proposal gives pharma more time to transition its global supply chain and reshore generic drug production.</p>
- Publication
- Supply Chain Dive · Trade Publication
- Published
- 4th August 2026
- Original report
- supplychaindive.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Supply Chain & Logistics
- Geography
- US
- Organisations
- None identified
- Collected
- 4th August 2026 · 15:20
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Moderate (36.0/100). Strongest contributor: Procurement Impact (27.0/30 points). Limiting factor: Impact-Scale Specificity (0.0/10 points). Initial Confidence Low (25.5/100, data sufficiency: Insufficient). Strongest contributor: Source Authority (20.0/40 points). Limiting factor: Specificity (0.0/20 points).
- Strongest contributor
- Procurement Impact
- Limiting factor
- Impact-Scale Specificity